Lanean...

免疫检查点抑制剂一线治疗晚期NSCLC的现状与展望

With the breakthroughs achieved of programmed death-1 (PD-1)/PD-L1 inhibitors monotherapy as first-line and second-line treatment in advanced non-small cell lung cancer (NSCLC), the treatment strategy is gradually evolving and optimizing. Immune combination therapy expands the benefit population and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Zhongguo Fei Ai Za Zhi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 中国肺癌杂志编辑部 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5973355/
https://ncbi.nlm.nih.gov/pubmed/28641702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2017.06.10
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!